World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai
LONDON--(BUSINESS WIRE)-- The Royal Marsden NHS Foundation Trust, a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA, a global leader in digital business and technology services, and CARPL.ai, a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes.
AI's potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK's National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This will lead to faster response times, more accurate diagnoses and better-targeted treatments.
The service runs on a MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the CARPL.ai platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models.
NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms.
'AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,' said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. 'By working with NTT DATA and CARPL.ai, we've created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.'
Minister of State for Health, Karin Smyth, said: 'Our 10 Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care.'
Professor Mike Lewis, NIHR Scientific Director for Innovation, said: "Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis.
"This AI-powered service represents the cutting edge of cancer research and it is going to transform treatment, better support NHS staff and ultimately change patients' lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it.'
Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: 'This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.'
Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through CARPL.ai's centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research which will ultimately improve cancer care and patient outcomes.
About NTT DATA
NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, and industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the world's leading providers of digital and AI infrastructure. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future.
Visit us at https://uk.nttdata.com/
About The Royal Marsden NHS Foundation Trust
The Royal Marsden opened in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer center and the Trust was delighted to welcome Her Royal Highness The Princess of Wales, who became Joint Patron with His Royal Highness The Prince of Wales, in January this year.
Together with its principal academic partner, The Institute of Cancer Research (ICR), The Royal Marsden is designated as the UK's only National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) dedicated solely to cancer.
The Royal Marsden and the ICR are recognized as one of the top four comprehensive cancer centers in the world for the impact of their research, influencing cancer treatment and care for all cancer patients. It is a center of excellence, pioneering the very latest in cancer treatments and technologies, as well as leading the way in innovative cancer diagnosis and education.
The Royal Marsden operates from three centers, in Chelsea, Sutton and Cavendish Square in central London. It also has a Medical Day Unit in Kingston, and is the founder and host of RM Partners West London Cancer Alliance, which includes St George's University Hospitals NHS Foundation Trust, Imperial Healthcare NHS Trust, and other healthcare partners across north west and south west London.
Driven by the fundamental principle that patients, entrusting their lives to The Royal Marsden, deserve the very best, The Royal Marsden is committed to delivering excellent research‑led cancer care for patients, accelerating early diagnosis, and ensuring treatment and care is personalized for the needs of each individual.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Markets Close in Green on Mostly Quiet Trading Day
Monday, June 2, 2025Markets closed flat-to-up on this first trading day of the last month of calendar Q2. The Dow, which had collapsed -416 points at session lows, finished +35 points, +0.08%. The S&P 500 rose +24 points, +0.41%, while the Nasdaq outperformed the field: +128 points, +0.67%. The small-cap Russell 2000 rose +0.19% on the recent trade tensions — specifically, the raised tariff on steel and aluminum to +50% announced by President Trump late Friday — were a renewed interest in the AI trade once again supported tech stocks, while oil companies caught a bid on $63 barrels of oil today. All in all, it was a quiet day for data, relatively: Jobs Week reports begin with the JOLTS numbers out Tuesday morning. For the month of May, S&P final Manufacturing PMI and ISM Manufacturing reports showed a slight decline on the former and an in-line print on the latter. The S&P headline of 52.0 was 30 basis points (bps) below estimates, which were flat month over month. ISM came in at +48.5% — as expected and down 20 bps from the April headline, but still below the 50 threshold between growth and loss. Analysts had been expecting a rebound into positive Construction Spending for April, but at -0.4% this headline came 60 bps below estimates to +0.2%. This followed -0.8% print for March, which was the lowest we've seen since September of last year. It also marks the thirds negative month in the first four for 2025. The April totals of the Job Openings and Labor Turnover Survey (JOLTS) hit the tape Tuesday morning. They are expected to tick down month over month to 7.1 million from 7.2 million reported, and are the first in a series of labor force data this week, which we call Jobs Orders, also for April, will be out tomorrow as well, after the opening bell. Much like the downturn in Construction Spending we saw today for April, Factory Orders are expected to dip into negative territory, likely based on questions and concerns related to the trade war. Orders are forecast to reach -3.3% for the month from +4.3% reported for while we basically consider calendar Q1 earnings season completed, we still have a few companies of consequence reporting this week. Among them, Dollar General DG, up +28% year to date, is expected to deliver negative -10.9% earnings per share on +3.76% in revenue growth. That will be before the opening bell Tuesday. After the market closes, cybersecurity major CrowdStrike CRWD is projected to bring negative -29% earnings per share growth on +20% in revenues. This company has never missed an earnings estimate since its 2019 or comments about this article and/or author? Click here>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dollar General Corporation (DG) : Free Stock Analysis Report CrowdStrike (CRWD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Stocks brave tariff-induced volatility to swing higher
Stock indexes closed higher on Monday despite uncertain economic news as Trump's tariffs continue to be fought over in court. After posting their strongest month since 2023 in May, stocks started off June on a strong foot. Indexes opened in the red but closed higher Monday, powering through a poor manufacturing report and ongoing uncertainty over U.S. trade negotiations. The S&P 500 closed 0.3% higher. The Dow gained 0.08% and the Nasdaq gained 0.7%. Nvidia gained 2.2% and Meta rose 3.6%, helping pull the overall index higher. According to the Institute for Supply Management's manufacturing report this morning, the sector contracted for the third month in a row, with new orders, backlogs, production, and employment all shrinking. Respondents to the ISM's monthly survey overwhelmingly cited uncertainty about tariffs and higher input costs as challenges. 'In May, U.S. manufacturing activity slipped further into contraction after expanding only marginally in February,' Susan Spence, chair of the ISM's Manufacturing Business Survey Committee, said in a statement. She added that deliveries were delayed because of additional processing time at ports and because 'suppliers and panelists' companies are haggling over who pays for applied tariffs.' Last week, an appeals court permitted the Trump administration's tariffs to stay in place while lawsuits on their legality proceed, potentially going all the way up to the Supreme Court. However, even if the current 'reciprocal' tariffs are ruled illegal, analysts note, the White House has several legal options to pursue its tariff policies. 'Either way, tariff rates are likely to get back over 10% and stay there, one way or another,' researchers at LPL Financial said in a note. 'Trade negotiations will continue, economic growth and deficit concerns will remain, and markets are likely to continue to be volatile around lingering trade policy uncertainty.' This story was originally featured on Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
S&P closes higher on trade hopes, Nvidia lifts Nasdaq
STORY: U.S. stocks closed higher on Monday, with the Dow just nudging into the green, the S&P 500 rising four-tenths of a percent and the Nasdaq adding two-thirds of a percent. Investors by the end of the session shrugged off President Donald Trump's latest salvo to double tariffs on imported steel and aluminum to 50%. But Sam Stovall, chief investment strategist at CFRA Research, thinks that despite months of flip-flopping on trade policy, Trump this time should be taken at his word. "I think the 50% tariff placed on steel and aluminum is not just rhetoric, it's reality. It is something that is going to last possibly through the entire Trump administration. Our Washington analysis political strategy arm believes that what the administration is trying to do is to drive new capacity within the U.S. for both steel and aluminum production, rather than simply trying to use this as a negotiating ploy." Shares of U.S. steel companies rose, led by Cleveland-Cliffs, which surged 23%. Other steel-makers also gained, including Nucor and Steel Dynamics. But shares of automakers dropped, with Ford closing down almost 4% and General Motors also falling by a similar percentage. The Nasdaq got a boost from shares of Nvidia as well as shares of Meta, which gained more than three-and-a-half percent. And shares of Tesla lost ground after the EV maker reported lower monthly sales for Portugal, Denmark and Sweden. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
